化合物 C3001a T71955
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 3
- 1
Product IntroductionBioactivity英文名: C3001a描述: C3001a is a selective activator for TREK, against other two-pore domain K+(
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: C3001a
描述: C3001a is a selective activator for TREK, against other two-pore domain K+(K2P) channels. C3001a binds to the cryptic binding site formed by P1 and TM4 in TREK-1. C3001a targets TREK channels in the peripheral nervous system to reduce the excitability of nociceptive neurons. In neuropathic pain, C3001a alleviated spontaneous pain and cold hyperalgesia. In a mouse model of acute pancreatitis, C3001a alleviated mechanical allodynia and inflammation. C3001a represents a lead compound which could advance the rational design of peripherally acting analgesics targeting K2P channels without opioid-like adverse effects.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
关键字: BHV3000 | BMS-927711 | BMS 927711 | C3001a | BHV 3000 | Rimegepant | BMS927711
Bioactivity
英文名: C3001a
描述: C3001a is a selective activator for TREK, against other two-pore domain K+(K2P) channels. C3001a binds to the cryptic binding site formed by P1 and TM4 in TREK-1. C3001a targets TREK channels in the peripheral nervous system to reduce the excitability of nociceptive neurons. In neuropathic pain, C3001a alleviated spontaneous pain and cold hyperalgesia. In a mouse model of acute pancreatitis, C3001a alleviated mechanical allodynia and inflammation. C3001a represents a lead compound which could advance the rational design of peripherally acting analgesics targeting K2P channels without opioid-like adverse effects.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
关键字: BHV3000 | BMS-927711 | BMS 927711 | C3001a | BHV 3000 | Rimegepant | BMS927711
猜你喜欢
感兴趣产品